Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Sokal and Hasford scoring systems are established prognostic models for chronic myeloid leukemia (CML).
• The predictive accuracy of these models in elderly CML patients with comorbidities remains unclear.
• Comorbidities can influence treatment response and survival in various cancers.

Purpose of the Study:

• To evaluate the association between comorbidity at diagnosis and treatment outcomes in chronic phase CML patients.
• To assess the impact of comorbidities on survival in CML patients treated with tyrosine kinase inhibitors (TKIs).

Main Methods:

• A cohort of 79 chronic phase CML patients diagnosed between 2001 and 2012 and treated with TKIs was studied.
• The Charlson Comorbidity Index (CCI) was used to quantify comorbidity burden at diagnosis.
• Treatment outcomes, including major molecular response and complete cytogenetic response, and overall survival were analyzed.

Main Results:

• A significant proportion of patients (27/79) had a CCI score greater than 3.
• Patients with a CCI score >3 exhibited significantly poorer survival compared to those with lower scores.
• CCI scores were inversely associated with overall survival, indicating higher comorbidity predicts worse outcomes.
• Major molecular response was achieved in 46 patients, and complete cytogenetic response in 73.4% at 12 months.

Conclusions:

• Concomitant comorbidity at diagnosis is a significant negative prognostic factor in CML patients treated with TKIs.
• The Charlson Comorbidity Index is a valuable tool for predicting outcomes in this patient population.
• Comorbidity assessment should be integrated into prognostic models for CML, especially in older adults.